Dosing & Administration Guide

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam faucibus tortor nec nunc cursus bibendum accumsan et nisl. Etiam porttitor ultrices enim in volutpat. Mauris auctor nulla at suscipit cursus. Donec tempus egestas tellus nec pellentesque. Quisque interdum sit amet nisl id ultricies. Donec sit amet erat magna. Aliquam erat volutpat. Ut tortor risus, tempus et fringilla eget, vulputate non arcu. Vestibulum suscipit nibh sit amet augue congue, venenatis condimentum lacus ultricies. Nulla et porta risus, eget faucibus elit. Sed at erat mattis lorem viverra lacinia fringilla id erat. Quisque lectus massa, ornare nec diam et, ultricies iaculis purus. Integer sed mattis lorem, et laoreet nunc. Etiam faucibus aliquam diam in vestibulum. Nullam vel vulputate magna. Fusce ultricies eleifend massa sit amet placerat.

Nulla eget fermentum tortor. Nunc varius lorem sit amet neque dapibus, sit amet semper lacus pharetra. Phasellus laoreet sapien tellus, non laoreet lacus aliquet vel. Curabitur molestie, purus at molestie eleifend, diam odio auctor nisl, vel consequat nisi augue sit amet purus. Curabitur faucibus placerat molestie. Suspendisse porttitor iaculis risus vitae viverra. Aliquam maximus, lectus faucibus pharetra commodo, tellus nisl finibus sem, non bibendum est lorem id arcu. Cras eget porta erat. In pulvinar erat felis, a mollis sem interdum quis. Praesent egestas turpis id risus congue, vel bibendum eros blandit. Duis urna ex, gravida nec molestie nec, pretium ac felis. Suspendisse elementum, lacus eu condimentum vulputate, nulla enim posuere urna, non ultrices dui arcu sed nulla.

Duis aliquam dui a tortor egestas, sit amet dignissim elit mattis. Aliquam pellentesque, odio vel malesuada vulputate, est turpis sagittis est, sed dictum velit justo nec risus. Vestibulum sollicitudin auctor condimentum. Suspendisse placerat nulla eu nunc porttitor fringilla. Aenean feugiat sed lacus ut hendrerit. Praesent elit sem, faucibus quis elementum ac, aliquam eget enim. Etiam at viverra risus, ut semper tortor. Vestibulum magna turpis, luctus ut arcu nec, imperdiet vestibulum urna. Nam vel pretium ipsum. Proin iaculis faucibus felis, et volutpat est tincidunt in.

Ut condimentum quam ut urna posuere viverra. Suspendisse rutrum quis lorem vitae rhoncus. Donec aliquet pharetra sapien a tincidunt. Morbi egestas magna sit amet semper venenatis. Aliquam erat volutpat. Phasellus quam urna, aliquet in tellus quis, consequat lacinia massa. Aenean vel aliquet turpis, ac interdum massa. Duis eget lectus blandit velit dignissim accumsan. Nam tempor eget leo sit amet bibendum.

Aliquam ac mi hendrerit, porttitor lectus et, lacinia augue. Vestibulum hendrerit, sapien sed mattis porta, ligula mi tincidunt magna, quis tincidunt orci felis sit amet felis. Nam viverra, leo id vestibulum malesuada, nisl massa ornare elit, a faucibus diam augue vulputate augue. Duis cursus massa eget turpis aliquam, et efficitur urna dapibus. Aliquam erat volutpat. Donec quis mauris at ligula congue tincidunt. Proin convallis, erat vitae consectetur sollicitudin, libero urna gravida orci, nec congue ipsum risus sed ipsum. Aenean eget ante diam. Vivamus et aliquam arcu, nec pharetra mauris. In ipsum felis, commodo at suscipit vitae, auctor id dolor. Maecenas congue feugiat sagittis. Praesent aliquet ex varius dui consequat euismod. Etiam vestibulum eget tortor in sollicitudin. Fusce vel mauris vitae justo hendrerit consequat sit amet at turpis.

Indication and Usage

ZYNLONTA® is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Important Safety Information

WARNINGS AND PRECAUTIONS

Effusion and Edema

Serious effusion and edema occurred in patients treated with ZYNLONTA®. Grade 3 edema occurred in 3% (primarily peripheral edema or ascites) and Grade 3 pleural effusion occurred in 3% and Grade 3 or 4 pericardial effusion occurred in 1%.

Monitor patients for new or worsening edema or effusions. Withhold ZYNLONTA® for Grade 2 or greater edema or effusion until the toxicity resolves. Consider diagnostic imaging in patients who develop symptoms of pleural effusion or pericardial effusion, such as new or worsened dyspnea, chest pain, and/or ascites such as swelling in the abdomen and bloating. Institute appropriate medical management for edema or effusions.

Myelosuppression

Treatment with ZYNLONTA® can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Grade 3 or 4 neutropenia occurred in 32%, thrombocytopenia in 20%, and anemia in 12% of patients. Grade 4 neutropenia occurred in 21% and thrombocytopenia in 7% of patients. Febrile neutropenia occurred in 3%.

Monitor complete blood counts throughout treatment. Cytopenias may require interruption, dose reduction, or discontinuation of ZYNLONTA®. Consider prophylactic granulocyte colony-stimulating factor administration as applicable.

Infections

Fatal and serious infections, including opportunistic infections, occurred in patients treated with ZYNLONTA®. Grade 3 or higher infections occurred in 10% of patients, with fatal infections occurring in 2%. The most frequent Grade ≥3 infections included sepsis and pneumonia.

Monitor for any new or worsening signs or symptoms consistent with infection. For Grade 3 or 4 infection, withhold ZYNLONTA® until infection has resolved.

Cutaneous Reactions

Serious cutaneous reactions occurred in patients treated with ZYNLONTA®. Grade 3 cutaneous reactions occurred in 4% and included photosensitivity reaction, rash (including exfoliative and maculo-papular), and erythema.

Monitor patients for new or worsening cutaneous reactions, including photosensitivity reactions. Withhold ZYNLONTA® for severe (Grade 3) cutaneous reactions until resolution. Advise patients to minimize or avoid exposure to direct natural or artificial sunlight including exposure through glass windows. Instruct patients to protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products. If a skin reaction or rash develops, dermatologic consultation should be considered.

Embryo-Fetal Toxicity

Based on its mechanism of action, ZYNLONTA® can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (SG3199) and affects actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ZYNLONTA® and for 9 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZYNLONTA® and for 6 months after the last dose.

ADVERSE REACTIONS

In a pooled safety population of 215 patients (Phase 1 and LOTIS-2), the most common (>20%) adverse reactions, including laboratory abnormalities, were thrombocytopenia, increased gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain.

In LOTIS-2, serious adverse reactions occurred in 28% of patients receiving ZYNLONTA®. The most common serious adverse reactions that occurred in ≥2% receiving ZYNLONTA® were febrile neutropenia, pneumonia, edema, pleural effusion, and sepsis. Fatal adverse reactions occurred in 1%, due to infection.

Permanent treatment discontinuation due to an adverse reaction of ZYNLONTA® occurred in 19% of patients. Adverse reactions resulting in permanent discontinuation of ZYNLONTA® in ≥2% were gamma-glutamyltransferase increased, edema, and effusion.

Dose reductions due to an adverse reaction of ZYNLONTA® occurred in 8% of patients. Adverse reactions resulting in dose reduction of ZYNLONTA® in ≥4% was gamma-glutamyltransferase increased.

Dosage interruptions due to an adverse reaction occurred in 49% of patients receiving ZYNLONTA®. Adverse reactions leading to interruption of ZYNLONTA® in ≥5% were gamma-glutamyltransferase increased, neutropenia, thrombocytopenia, and edema.

DOSE DELAYS AND MODIFICATIONS

For any Grade 3 or greater nonhematologic toxicity, ZYNLONTA® should be held until the toxicity resolves to Grade 1 or less. For neutropenia: if absolute neutrophil count is <1 x 109/L, withhold ZYNLONTA® until the neutrophil count returns to 1 x 109/L or higher. For thrombocytopenia: if platelet count is <50,000/mcL, withhold ZYNLONTA® until the platelet count returns to 50,000/mcL or higher. For Grade 2 or greater edema or effusion, ZYNLONTA® should be held until the toxicity resolves to Grade 1 or less. If dosing is delayed by more than 3 weeks due to toxicity related to ZYNLONTA®, reduce subsequent doses by 50%. If toxicity reoccurs following dose reduction, consider discontinuation. Note: If toxicity requires dose reduction following the second dose of 0.15 mg/kg (C2D1), the patient should receive the dose of 0.075 mg/kg for Cycle 3.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for additional Important Safety Information.